Journal of Diagnostics Concepts & Practice >
Research progress on positron emission tomography using radionuclide-labeled fibroblast activation protein inhibitor in diagnosis of cardiac diseases
Received date: 2025-01-03
Accepted date: 2025-03-09
Online published: 2025-07-11
Fibroblast activation protein (FAP) is a type Ⅱ transmembrane serine protease specifically expressed on the surface of activated cardiac fibroblasts (CFs). During myocardial injury, inflammation, and fibrosis, it drives myocardial interstitial remodeling and collagen deposition by degrading the extracellular matrix and activating key pathways such as transforming growth factor-β (TGF-β), thus serving as a central effector target in the development of myocardial fibrosis. FAP is significantly upregulated exclusively in activated CFs, with minimal expression in normal myocardial tissue, provi-ding a molecular basis for the non-invasive and precise diagnosis of cardiac diseases. In recent years, radionuclide-labeled FAP inhibitor (FAPI) positron emission tomography (PET), with its non-invasiveness, high targeting specificity, and quantitative evaluation capability, has enabled the early detection of microfibrosis signals at the molecular level. This technique overcomes the reliance of conventional imaging (e.g., cardiac magnetic resonance) on structural changes, demonstrating unique advantages in the dynamic evaluation of active myocardial fibrosis and providing a novel pathway for early diagnosis, exploration of pathological mechanisms, and prognostic evaluation of cardiac diseases. Current research confirms that FAPI-PET holds significant application value across multiple cardiac diseases. For example, in left ventricular remodeling after acute myocardial infarction, dynamic monitoring of FAP activity in the peri-infarct zone can predict ventricular dilation and adverse remodeling trends. In cardiotoxicity induced by radiotherapy, chemotherapy, or immunotherapy, it achieves early warning of subclinical fibrosis. For cardiac amyloidosis, it facilitates early quantification of myocardial fibrotic burden and assists in risk stratification and prognosis evaluation across different subtypes. In pulmonary hypertension and right ventricular remodeling, it can comprehensively evaluate diffuse fibrosis and reflect the severity of the di-sease. For different subtypes of cardiomyopathy (e.g., hypertrophic/dilated), it assists in clinical phenotype identification by analyzing the spatial distribution of fibrosis. Additionally, it can be used to evaluate the atrial injury repair responses after catheter ablation for atrial fibrillation, thereby predicting the risk of arrhythmia recurrence. This study reviews domestic and international research advances in the application of FAPI-PET in the diagnosis of cardiac diseases, and discusses its application potential and future challenges.
JIA Yingqi , ZHANG Min , LI Biao . Research progress on positron emission tomography using radionuclide-labeled fibroblast activation protein inhibitor in diagnosis of cardiac diseases[J]. Journal of Diagnostics Concepts & Practice, 2025 , 24(02) : 220 -225 . DOI: 10.16150/j.1671-2870.2025.02.014
| [1] | VARASTEH Z, MOHANTA S, ROBU S, et al. Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04[J]. J Nucl Med,2019,60(12):1743-1749. |
| [2] | NAGARAJU C K, DRIES E, POPOVIC N, et al. Global fibroblast activation throughout the left ventricle but localized fibrosis after myocardial infarction[J]. Sci Rep,2017,7(1):10801. |
| [3] | HUMEREZ C, FRANGOGIANNIS N G. Fibroblasts in the infarcted, remodeling, and failing heart[J]. JACC Basic Transl Sci,2019,4(3):449-467. |
| [4] | VAN HOUT G P, ARSLAN F, PASTERKAMP G, et al. Targeting danger-associated molecular patterns after myocardial infarction[J]. Expert Opin Ther Targets,2016,20(2):223-239. |
| [5] | BLANKESTEIJN W M. Has the search for a marker of activated fibroblasts finally come to an end?[J]. J Mol Cell Cardiol,2015,88:120-123. |
| [6] | ROG-ZIELINSKA E A, NORRIS R A, KOHL P, et al. The living scar—cardiac fibroblasts and the injured heart[J]. Trends Mol Med,2016,22(2):99-114. |
| [7] | KESSLER L, KUPUSOVIC J, FERDINANDUS J, et al. Visualization of fibroblast activation after myocardial infarction using 68Ga-FAPI PET[J]. Clin Nucl Med,2021,46(10):807-813. |
| [8] | DIEKMANN J, KOENIG T, THACKERAY J T, et al. Cardiac fibroblast activation in patients early after acute myocardial infarction: integration with MR tissue characteri-zation and subsequent functional outcome[J]. J Nucl Med,2022,63(9):1415-1423. |
| [9] | SIEBERMAIR J, K?HLER M I, KUPUSOVIC J, et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling[J]. J Nucl Cardiol,2021,28(3):812-821. |
| [10] | XIE B, WANG J, XI X Y, et al. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging[J]. Eur J Nucl Med Mol Imaging,2022,49(8):2786-2797. |
| [11] | ZHANG M, QUAN W, ZHU T, et al. [68Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling[J]. Eur J Nucl Med Mol Imaging,2023,50(3):839-848. |
| [12] | SHARMA P, SINGH S S, GAYANA S. Fibroblast activation protein inhibitor PET/CT: a promising molecular imaging tool[J]. Clin Nucl Med,2021,46(3):e141-e150. |
| [13] | PRABHU S D, FRANGOGIANNIS N G. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis[J]. Circ Res,2016,119(1):91-112. |
| [14] | IBANEZ B, ALETRAS A H, ARAI A E, et al. Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel[J]. J Am Coll Cardiol,2019,74(2):238-256. |
| [15] | VAZIR A, FOX K, WESTABY J, et al. Can we remove scar and fibrosis from adult human myocardium?[J]. Eur Heart J,2019,40(12):960-966. |
| [16] | HOFFMANN D B, FRACCAROLLO D, GALUPPO P, et al. Genetic ablation of fibroblast activation protein alpha attenuates left ventricular dilation after myocardial infarction[J]. PLoS One,2021,16(3):e0248196. |
| [17] | TAPIO S. Pathology and biology of radiation-induced cardiac disease[J]. J Radiat Res,2016,57(5):439-448. |
| [18] | CHANG H M, MOUDGIL R, SCARABELLI T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1[J]. J Am Coll Cardiol,2017,70(20):2536-2551. |
| [19] | GABRIELS K, HOVING S, SEEMANN I, et al. Local heart irradiation of ApoE(-/-) mice induces microvascular and endocardial damage and accelerates coronary atherosclerosis[J]. Radiother Oncol,2012,105(3):358-364. |
| [20] | HECKMANN M B, REINHARDT F, FINKE D, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease[J]. Circ Cardiovasc Imaging,2020,13(9):e010628. |
| [21] | JOHNSON D B, BALKO J M, COMPTON M L, et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med,2016,375(18):1749-1755. |
| [22] | NIU N, HUO L, ZHANG S, et al. Immune checkpoint inhibitor-associated cardiotoxicity detected by 68Ga-DOTATATE PET/CT and 68Ga-FAPI PET/CT[J]. Eur Heart J Cardiovasc Imaging,2022,23(3):e123. |
| [23] | WANG H, WEI J, ZHENG Q, et al. Radiation-induced heart disease: a review of classification, mechanism and prevention[J]. Int J Biol Sci,2019,15(10):2128-2138. |
| [24] | FONTANA M, COROVIC A, SCULLY P, et al. Myocardial amyloidosis: the exemplar interstitial disease[J]. JACC Cardiovasc Imaging,2019,12(11 Pt 2):2345-2356. |
| [25] | GROGAN M, DISPENZIERI A, GERTZ M A. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response[J]. Heart,2017,103(14):1065-1072. |
| [26] | RUBERG F L, BERK J L. Transthyretin (TTR) cardiac amyloidosis[J]. Circulation,2012,126(10):1286-1300. |
| [27] | FALK R H, QUARTA C C. Echocardiography in cardiac amyloidosis[J]. Heart Fail Rev,2015,20(2):125-131. |
| [28] | MARTINEZ-NAHARRO A, TREIBEL T A, ABDEL-GADIR A, et al. Magnetic resonance in transthyretin cardiac amyloidosis[J]. J Am Coll Cardiol,2017,70(4):466-477. |
| [29] | YANG M, ARSANJANI R, ROARKE M C. Advanced nuclear medicine and molecular imaging in the diagnosis of cardiomyopathy[J]. Am J Roentgenol,2020,215(5):1208-1217. |
| [30] | YAMAMOTO Y, ONOGUCHI M, HARAMOTO M, et al. Novel method for quantitative evaluation of cardiac amyloidosis using 201TlCl and 99mTc-PYP SPECT[J]. Ann Nucl Med,2012,26(8):634-643. |
| [31] | WANG X, GUO Y, GAO Y, et al. Feasibility of 68Ga-labeled fibroblast activation protein inhibitor PET/CT in light-chain cardiac amyloidosis[J]. JACC Cardiovasc Imaging,2022,15(11):1960-1970. |
| [32] | DORBALA S. Fibroblast activation: a novel mechanism of heart failure in light chain cardiac amyloidosis?[J]. JACC Cardiovasc Imaging,2022,15(11):1971-1973. |
| [33] | GUO W, CHEN H. 68Ga FAPI PET/MRI in cardiac amyloidosis[J]. Radiology,2022,303(1):51. |
| [34] | CAHILL T J, ASHRAFIAN H, WATKINS H. Genetic cardiomyopathies causing heart failure[J]. Circ Res,2013,113(6):660-675. |
| [35] | CHALHOUB S M, LOH P, HAUER R N, et al. The role of connexin40 in atrial fibrillation[J]. Cardiovasc Res,2009,84(1):15-23. |
| [36] | MORAVSKY G, OFEK E, RAKOWSKI H, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR[J]. JACC Cardiovasc Imaging,2013,6(5):587-596. |
| [37] | ALMAAS V M, HAUGAA K H, STR?M E H, et al. Noninvasive assessment of myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy[J]. Heart,2014,100(8):631-638. |
| [38] | ZHANG Y, DONG Z, WANG L, et al. Functional significance of myocardial activity at 18F-FAPI PET/CT in hypertrophic cardiomyopathy identified by cardiac magnetic resonance feature-tracking strain analysis[J]. Eur J Nucl Med Mol Imaging,2023,51(1):110-122. |
| [39] | SHI X, LIN X, HUO L, et al. Cardiac fibroblast activation in dilated cardiomyopathy detected by positron emission tomography[J]. J Nucl Cardiol,2022,29(2):881-884. |
| [40] | LIN K, CHEN X, XUE Q, et al. Diffuse uptake of [68Ga]Ga-FAPI in the left heart in a patient with hypertensive heart disease by PET/CT[J]. J Nucl Cardiol,2022,29(6):3596-3598. |
| [41] | HO C Y, LOPEZ B, COELHO-FILHO O R, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy[J]. N Engl J Med,2010,363(6):552-563. |
| [42] | WANG L, WANG Y, WANG J, et al. Myocardial activity at 18F-FAPI PET/CT and risk for sudden cardiac death in hypertrophic cardiomyopathy[J]. Radiology,2023,306(2):e221052. |
| [43] | AGHAJANIAN H, KIMURA T, RURIK J G, et al. Targe-ting cardiac fibrosis with engineered T cells[J]. Nature,2019,573(7774):430-433. |
| [44] | WANG J, HUO L, LIN X, et al. Molecular imaging of fibroblast activation in multiple non-ischemic cardiomyo-pathies[J]. EJNMMI Res,2023,13(1):39. |
| [45] | ZENG X, ZHAO R, WU Z, et al. [18F]-FAPI-42 PET/CT assessment of progressive right ventricle fibrosis under pressure overload[J]. Respir Res,2023,24(1):270. |
| [46] | XING H Q, GONG J N, CHEN B X, et al. Comparison of 68Ga-FAPI imaging and cardiac magnetic resonance in detection of myocardial fibrosis in a patient with chronic thromboembolic pulmonary hypertension[J]. J Nucl Cardiol,2022,29(5):2728-2730. |
| [47] | PATEL R B, LI E, BENEFIELD B C, et al. Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension[J]. ESC Heart Fail,2020,7(1):253-263. |
| [48] | WANG L, ZHANG Z, ZHAO Z, et al. 68Ga-FAPI right heart uptake in a patient with idiopathic pulmonary arterial hypertension[J]. J Nucl Cardiol,2022,29(3):1475-1477. |
| [49] | GONG J N, CHEN B X, XING H Q, et al. Pulmonary artery imaging with 68Ga-FAPI-04 in patients with chronic thromboembolic pulmonary hypertension[J]. J Nucl Cardiol,2023,30(3):1166-1172. |
| [50] | GU Y, HAN K, ZHANG Z, et al. 68Ga-FAPI PET/CT for molecular assessment of fibroblast activation in right heart in pulmonary arterial hypertension: a single-center, pilot study[J]. J Nucl Cardiol,2023,30(2):495-503. |
| [51] | CHEN B X, XING H Q, GONG J N, et al. Imaging of cardiac fibroblast activation in patients with chronic thromboembolic pulmonary hypertension[J]. Eur J Nucl Med Mol Imaging,2022,49(4):1211-1222. |
| [52] | KUPUSOVIC J, KESSLER L, NEKOLLA S G, et al. Visua-lization of thermal damage using 68Ga-FAPI-PET/CT after pulmonary vein isolation[J]. Eur J Nucl Med Mol Imaging,2022,49(5):1553-1559. |
| [53] | LINHART M, ALARCON F, BORRàS R, et al. Delayed gadolinium enhancement magnetic resonance imaging detected anatomic gap length in wide circumferential pulmonary vein ablation lesions is associated with recurrence of atrial fibrillation[J]. Circ Arrhythm Electrophysiol,2018,11(12):e006659. |
| [54] | HARRISON J L, SOHNS C, LINTON N W, et al. Repeat left atrial catheter ablation: cardiac magnetic resonance prediction of endocardial voltage and gaps in ablation lesion sets[J]. Circ Arrhythm Electrophysiol,2015,8(2):270-278. |
| [55] | KUCK K H, HOFFMANN B A, ERNST S, et al. Impact of complete versus incomplete circumferential lines around the pulmonary veins during catheter ablation of paroxysmal atrial fibrillation: results from the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 Trial[J]. Circ Arrhythm Electrophysiol,2016,9(1):e003337. |
| [56] | KUPUSOVIC J, KESSLER L, BRUNS F, et al. Visualization of fibroblast activation using 68Ga-FAPI PET/CT after pulmonary vein isolation with pulsed field compared with cryoballoon ablation[J]. J Nucl Cardiol,2023,30(5):2018-2028. |
/
| 〈 |
|
〉 |
